Report
Roche Holding : A more complex H2 and 2019 on the cards... Neutral vs Buy
>A very good first half (+7% at constant forex) but significant disparity between EU and US - There is no denying that Roche reported very good figures for Q2/H1 2018. Organic sales growth in Q2 came in at 7% for sales (pharma and diagnostics also up +7% at constant forex) and 19% for core EPS in H1. Management even raised its full-year guidance for the second time this year and is expecting sales growth in the mid-single digits and core EPS growth in the mid-teens. A...
Underlying
Roche Holding AG
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oussema Denguir
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.